Pages that link to "Q45993642"
Jump to navigation
Jump to search
The following pages link to ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. (Q45993642):
Displaying 50 items.
- Pharmacogenetics, pharmacogenomics, and individualized medicine (Q23919667) (← links)
- The multidrug transporter ABCG2: still more questions than answers (Q26747187) (← links)
- Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review (Q26823434) (← links)
- Pediatric Statin Administration: Navigating a Frontier with Limited Data (Q28068014) (← links)
- The Effect of Albumin on MRP2 and BCRP in the Vesicular Transport Assay (Q28554497) (← links)
- Membrane transporters in drug development (Q29616802) (← links)
- Racial Differences in the Cholesterol-Lowering Effect of Statin (Q30244632) (← links)
- ABC Transport Proteins in Cardiovascular Disease-A Brief Summary (Q30313271) (← links)
- Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design (Q30582571) (← links)
- Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective (Q30616911) (← links)
- Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin (Q33581531) (← links)
- Xenobiotic, bile acid, and cholesterol transporters: function and regulation. (Q33714593) (← links)
- Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) (Q34176588) (← links)
- Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin (Q34571070) (← links)
- The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. (Q34613443) (← links)
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins (Q34680467) (← links)
- Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update (Q34871636) (← links)
- The challenge of exploiting ABCG2 in the clinic. (Q34968909) (← links)
- Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers (Q35183649) (← links)
- The emerging role of electronic medical records in pharmacogenomics (Q35478918) (← links)
- Dyslipidemia in special ethnic populations (Q35573543) (← links)
- Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions (Q35915932) (← links)
- A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. (Q35917726) (← links)
- ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population (Q36050960) (← links)
- Improving cancer chemotherapy with modulators of ABC drug transporters (Q36108251) (← links)
- Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (Q36110576) (← links)
- What do drug transporters really do? (Q36571217) (← links)
- Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies (Q36620076) (← links)
- Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter (Q36733503) (← links)
- Current Perspectives on rosuvastatin (Q36796490) (← links)
- Drug-drug interaction studies: regulatory guidance and an industry perspective (Q36951933) (← links)
- Molecular mechanisms of statin intolerance (Q36958324) (← links)
- Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 (Q36998199) (← links)
- Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. (Q37017426) (← links)
- A perspective on efflux transport proteins in the liver (Q37050337) (← links)
- Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier (Q37164563) (← links)
- Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes (Q37331801) (← links)
- Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. (Q37331821) (← links)
- Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. (Q37392745) (← links)
- More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. (Q37394474) (← links)
- Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver (Q37504548) (← links)
- Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations (Q37533506) (← links)
- Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care (Q37579733) (← links)
- Transporter pharmacogenetics and statin toxicity (Q37627544) (← links)
- Pharmacogenetics of membrane transporters: an update on current approaches (Q37641869) (← links)
- Efflux and uptake transporters as determinants of statin response. (Q37724381) (← links)
- Drug transport by breast cancer resistance protein. (Q37793056) (← links)
- The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins (Q37810986) (← links)
- In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2) (Q37811967) (← links)
- Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins (Q37855801) (← links)